Kalray (FR0010722819 - ALKAL), a pioneer in processors for new intelligent systems, is proud to announce inline processing and artificial intelligence at the International SuperComputing trade show in

DevOps Enterprise Summit #DOES18 -- CollabNet VersionOne (www.collabnet.com), a global leader in Enterprise Value Stream Management, ALM, and Agile-plus-DevOps, today announced its Enterprise...

Heaven Springs Dynasty Harvest Group (HSDH Group) attended the UN's International High-Level Conference on the Water Action Decade conference in Dushanbe, Tajikistan, and is a partner for the...

BroadcastAsia 2018 -- Verimatrix, a specialist in securing and enhancing revenue for network-connected devices and services, today announced delivery and implementation of Verimatrix's...

LinuxCon + ContainerCon + CloudOpen – The Cloud Native Computing Foundation® (CNCF®), which sustains and integrates open source technologies like Kubernetes® and Prometheus™, today...

LinuxCon China -- The Linux Foundation, the nonprofit organization enabling mass innovation through open source, today announced at LinuxCon + ContainerCon + CloudOpen China in Beijing that TARS,...

LINUXCON CHINA --The Linux Foundation, the nonprofit organization enabling mass innovation through open source, has released Chinese translations of 10 Open Source Guides for the Enterprise,...

LinuxCon China -- The Linux Foundation, the nonprofit organization enabling mass innovation through open source, announces Tencent has become the latest Platinum member of the foundation. Tencent...

China is stepping into a new phase in this new age, is deeply implementing innovation-driven strategy, is speeding up building of an innovative state and is continuously promoting "Mass...

SMART Technologies launches new research at ISTE 2018 including a personalized profile configurator for schools to assess individual EdTech capabilities CALGARY, Alberta and CHICAGO, June 24, 2018...

Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that an abstract of a study in a preclinical...

People with type 1 diabetes (T1D) who take 200 mg or 400 mg of sotagliflozin in addition to optimized insulin therapy have statistically lower HbA1c levels and weight, as well as low incidence of...

Adding the selective SGLT2 inhibitor dapagliflozin to intensive insulin therapy in adults with type 1 diabetes (T1D) who had sub-optimal glycemic control reduced blood glucose levels, aided in...

Canagliflozin does not increase the risk of amputation for the general type 2 diabetes (T2D) population or in patients with established cardiovascular disease, but does reduce a patient's risk of...

When patients with type 2 diabetes (T2D) receive intensified, multifactorial treatment combining lifestyle modification and pharmacological therapy for modifiable risk factors, there is no...

People with diabetes who have experienced recent acute coronary syndrome (ACS) and take a combination of alirocumab and statins may reduce their risk of future cardiac events by more than double...

Adults with type 1 diabetes (T1D) who take a daily dose of liraglutide demonstrated improvements in HbA1c levels, weekly average blood glucose levels and increased weight loss, according to the...

One Drop, a leader in the development of digital therapeutics solutions for people with diabetes, today announced the launch of Blood Glucose Prediction and Automated Decision Support. Through...

New research finds that people with type 1 diabetes (T1D) who used the Diabeloop DBLG1 therapeutic, closed-loop insulin delivery system in a home setting experienced a greater percentage of time...

When adolescents and adults with type 1 diabetes (T1D) used a new continuous glucose monitoring (CGM) device containing a sensor that can remain implanted in the arm for up to 180 days, the system...

A dual-hormone, artificial pancreas1 delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an...

Adults with type 1 diabetes using the Omnipod hybrid closed-loop system (the Horizon™ Automated Glucose Control System) were studied in a supervised outpatient hotel setting with unrestricted...

Findings from CONFIRM – a large, retrospective real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL versus insulin glargine...

Ozempic® (semaglutide) injection 0.5 mg or 1 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass...

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new findings from two real-world studies comparing sodium glucose co-transporter-2 inhibitor (SGLT2i) INVOKANA®...